이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중증 천식이 있는 12~80세 환자에서 Tezepelumab을 사용하여 천식 조절 및 임상 관해를 유지하면서 기본 천식 약물의 감소를 평가하기 위한 공개 라벨 연구. (ARRIVAL)

2026년 10월 12일 업데이트: AstraZeneca

테제펠루맙으로 치료받은 중증 천식 환자의 천식 조절 및 임상 완화를 유지하면서 기본 치료를 줄일 수 있는 가능성을 평가하기 위한 다기관, 무작위, 공개, 병렬 그룹, 제IIIb상 연구

The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..

Study details include:

  1. The study duration will be up to 72 weeks.
  2. The treatment duration will be up to 68 weeks.
  3. The visit frequency will be once every 4 weeks (Q4W).

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.

Approximately 65 sites in 10 countries will enrol adult and adolescent patients with severe uncontrolled asthma.

The study is divided into 5 phases as described below:

  • Screening/Run-in Phase (from Week -4 until Week 0, up to 4 Weeks)
  • Treatment Induction Phase (Week 0 to Week 4)
  • Treatment Continuation Phase (Week 4 to Week 24)
  • Tezepelumab Treatment With or Without ICS Step-down Therapy Phase (Week 24 to Week 56)
  • Maintenance Phase (Week 56 to Week 72)

연구 유형

중재적

등록 (실제)

310

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Aalborg, 덴마크, 9000
        • Research Site
      • Hvidovre, 덴마크, 2650
        • Research Site
      • Svendborg, 덴마크, 5700
        • Research Site
      • Vejle, 덴마크, 7100
        • Research Site
      • Augsburg, 독일, 86150
        • Research Site
      • Bonn, 독일, 53127
        • Research Site
      • Cottbus, 독일, 03050
        • Research Site
      • Hanover, 독일, 30625
        • Research Site
      • Mainz, 독일, 55128
        • Research Site
      • Chihuahua City, 멕시코, 31200
        • Research Site
      • Cuauhtémoc, 멕시코, 06700
        • Research Site
      • Monterrey, 멕시코, 64360
        • Research Site
    • California
      • Palmdale, California, 미국, 93551
        • Research Site
    • Colorado
      • Colorado Springs, Colorado, 미국, 80907
        • Research Site
    • Florida
      • Miami, Florida, 미국, 33136
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • Research Site
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • Research Site
    • New Jersey
      • New Brunswick, New Jersey, 미국, 08901
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73120
        • Research Site
    • Texas
      • McAllen, Texas, 미국, 78503
        • Research Site
      • Anderlecht, 벨기에, 1070
        • Research Site
      • Edegem, 벨기에, 2650
        • Research Site
      • Erpent, 벨기에, 5101
        • Research Site
      • Ghent, 벨기에, 9000
        • Research Site
      • Liège, 벨기에, 4000
        • Research Site
      • Haskovo, 불가리아, 6300
        • Research Site
      • Pleven, 불가리아, 5804
        • Research Site
      • Razgrad, 불가리아, 7200
        • Research Site
      • Rousse, 불가리아, 7002
        • Research Site
      • Sofia, 불가리아, 1431
        • Research Site
      • Sofia, 불가리아, 1154
        • Research Site
      • Stara Zagora, 불가리아, 6003
        • Research Site
      • Velika Tarnovo, 불가리아, 5250
        • Research Site
      • Badalona(Barcelona), 스페인, 08916
        • Research Site
      • Barcelona, 스페인, 08035
        • Research Site
      • Lugo, 스페인, 27002
        • Research Site
      • Madrid, 스페인, 28041
        • Research Site
      • Madrid, 스페인, 28040
        • Research Site
      • Madrid, 스페인, 28006
        • Research Site
      • Berazategui, 아르헨티나, 1104
        • Research Site
      • CABA, 아르헨티나, C1012AAR
        • Research Site
      • Concepción del Uruguay, 아르헨티나, 3260
        • Research Site
      • Mendoza, 아르헨티나, 5500
        • Research Site
      • Mendoza, 아르헨티나, M5500CCG
        • Research Site
      • Quilmes, 아르헨티나, B1878FNR
        • Research Site
      • Rosario, 아르헨티나, 2000
        • Research Site
      • Rosario, 아르헨티나, 2002
        • Research Site
      • San Miguel de Tucumán, 아르헨티나, 4000
        • Research Site
      • Santa Fe, 아르헨티나, 3000
        • Research Site
      • Belfast, 영국, BT9 7BL
        • Research Site
      • Liverpool, 영국, L7 8XP
        • Research Site
      • London, 영국, SE1 9RT
        • Research Site
      • Southampton, 영국, SO16 6YD
        • Research Site
      • Florence, 이탈리아, 50134
        • Research Site
      • Orbassano, 이탈리아, 10043
        • Research Site
      • Roma, 이탈리아, 00168
        • Research Site
      • Roma, 이탈리아, 00161
        • Research Site
      • Verona, 이탈리아, 37134
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 1M9
        • Research Site
    • Ontario
      • Ajax, Ontario, 캐나다, L1S 2J5
        • Research Site
      • Windsor, Ontario, 캐나다, N8X 1T3
        • Research Site
    • Quebec
      • Québec, Quebec, 캐나다, G1V 4G5
        • Research Site
      • Sherbrooke, Quebec, 캐나다, J1H 5N4
        • Research Site
    • Saskatchewan
      • Regina, Saskatchewan, 캐나다, S7N 5A2
        • Research Site
      • Créteil, 프랑스, 94000
        • Research Site
      • La Tronche, 프랑스, 38700
        • Research Site
      • Lyon, 프랑스, 69004
        • Research Site
      • Marseille, 프랑스, 13915
        • Research Site
      • Montpellier, 프랑스, 34295
        • Research Site
      • Strasbourg, 프랑스, 67091
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria at Visit 1 (Screening):

Informed Consent

  1. Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses for patients who are at or over the age of majority (as per local law). For patients who are less than the age of majority, in addition to providing their informed consent, the patients' legally authorised representative must also provide their informed assent (Appendix A 3).

    Age

  2. Patients must be 12 to 80 years of age inclusive, at the time of signing the ICF.

    Type of Patient and Disease Characteristics

  3. Documented medical record history for at least 12 months prior to Visit 1.

  4. Documented physician-diagnosed severe asthma within 10 years prior to Visit 1 (ie, severe asthma was not diagnosed more than 10 years prior) consisting of any of the following:

    1. FEV1 > 12% reversibility, OR
    2. Evidence of airflow variability (to show that lung function is altered over time): FEV1 ≥ 400 mL variability over time, OR
    3. Challenge tests that are positive on one of the below:

    (i) Methacholine - PD20 ≤ 8 mg/mL (ii) Mannitol - PD15 15% drop on FEV1 out of dose < than 635 mg of inhaled mannitol (iii) Exercise - 10% fall of FEV1

  5. ACQ-5 ≥ 1.5 and < 3.

  6. History of physician-diagnosed asthma that requires continuous treatment with high-dose ICS (as defined by GINA or highest approved dose per posology per country) plus a LABA for at least 6 months prior to Visit 1 (Appendix I). The ICS and LABA can be contained within a combination product or given by separate inhalers.

    Note: Additional maintenance asthma controller medications (eg, LTRAs, tiotropium, cromone, theophylline) are allowed.

  7. Pre-brochodilator FEV1 > 60% predicted and evidence of FEV1 reversibility of > 12% within 6 months prior to screening or at screening. Patients with normal lung function (FEV1 > 80%) need evidence of airflow variability as per inclusion criterion 4.

  8. Documented history of at least one asthma exacerbation requiring OCS bursts or requiring hospitalization within 12 months prior to Visit 1. An asthma exacerbation will be defined as a worsening of asthma symptoms that leads to any of the following:

    1. A temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day bolus/burst of systemic corticosteroids
    2. Or, an ER visit (defined as evaluation and treatment for < 24 hours in ER) due to asthma that required systemic corticosteroids (as per above)
    3. Or, an in-patient hospitalisation (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥ 24 hours).

    Sex and Contraceptive/Barrier Requirements

  9. Male or female.

    Female patients:

    • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of nonchildbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the induction phase without an alternative medical cause.

    • The following age-specific requirements apply:

      • Women < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone levels in the postmenopausal range.
      • Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
      • Adolescents: if patient is female and has reached menarche or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient will be considered a WOCBP.
  10. WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP patient and that the vasectomised partner has received medical assessment of the surgical success)
    • Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.
    • Cessation of contraception after this point should be discussed with a responsible physician

    Inclusion Criteria 5.1.2 Treatment Induction Phase at Visit 2 (Week 0):

    Before dosing with tezepelumab at Week 0, patients should fulfil the following criteria:

  11. ACQ-5 ≥ 1.5 and < 3.

  12. Demonstrated proper inhaler technique (patients with improper technique at screening may be trained during screening, but must demonstrate proper technique before enrollment).

  13. No excessive SABA use (should be < 5 puffs/day) or for patients using SMART therapy outside the US, no excessive use of SYMBICORT (should be ≤ 8 inhalations/day) or for US patients, no excessive use of AIRSUPRA (should be ≤ 12 inhalations/day).

Exclusion Criteria:

Medical Conditions

  1. Any clinically important pulmonary disease other than asthma (eg, active lung infection, chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or pulmonary or systemic diseases, other than asthma, that are associated with elevated peripheral EOS counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the study or the interpretation
    • Impede the patient's ability to complete the entire duration of study.
  3. A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.

  4. Current smokers or patients with smoking history ≥ 10 pack-years and patients using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.

  5. History of chronic alcohol or drug abuse within 12 months prior to Visit 1.

  6. Tuberculosis requiring treatment within the 12 months prior to Visit 1.

  7. History of known immunodeficiency disorder including a positive human immunodeficiency virus test at Visit 1, or the patient taking antiretroviral medications as determined by medical history and/or patient's verbal report.

  8. Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures requiring general anaesthesia or inpatient status for > 1 day during the conduct of the study.

  9. Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae.

    Prior/Concomitant Therapy

  10. Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1.

  11. OCS-dependent patients (received chronic OCS therapy [prednisone ≥ 5 mg/day or equivalent]) for at least 3 months preceding Visit 1.

  12. Daily use of maintenance corticosteroids for any reason.

  13. Treatment with systemic immunosuppressive/immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for OCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.

  14. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.

  15. Receipt of live attenuated vaccines 30 days prior to the date of Visit 1 and during the study.

  16. Patients that have been treated with bronchial thermoplasty in the last 12 months prior to Visit 1.

    Prior/Concurrent Clinical Study Experience

  17. Known history of sensitivity to any component of the tezepelumab formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.

  18. History of anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) following any biologic therapy.

  19. Concurrent enrolment in another clinical study involving an IMP.

    Diagnostic Assessments

  20. Any clinically meaningful abnormal finding in physical examination, haematology, clinical chemistry at Visit 1 which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.

  21. Evidence of active liver disease, including jaundice or AST, ALT, or ALP > 2 times the ULN at Visit 1.

  22. Positive hepatitis B surface antigen, hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.

    Other Exclusions

  23. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or AstraZeneca.

  24. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

  25. For women only: Pregnant, breastfeeding, or lactating women. A serum β-HCG pregnancy test must be drawn for WOCBP at the screening visit. If the results of the serum β-HCG cannot be obtained prior to dosing of the IMP, a patient may be enrolled on the basis of a negative urine pregnancy test, though serum β-HCG must still be obtained. If either test is positive, the patient should be excluded. Since urine and serum tests may miss a pregnancy in the first days after conception, relevant menstrual history and sexual history, including methods of contraception, should be considered. Any patient whose menstrual and/or sexual history suggests the possibility of early pregnancy should be excluded.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS

Asthma Control or Low Biomarkers - Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2

IMP. Subcutaneous injection. Unit dose strengths 210 mg.

다른 이름들:
  • 테즈스파이어®

AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

다른 이름들:
  • SYMBICORT® pMDI

AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

다른 이름들:
  • AIRSUPRA®

NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

다른 이름들:
  • 아리돌®

AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation

다른 이름들:
  • 사부마린, 알부테롤, 벤톨린 HFA, 프로에어 HFA, 프로벤틸 HFA
실험적: Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS

Asthma Control or Low Biomarkers - No Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2

IMP. Subcutaneous injection. Unit dose strengths 210 mg.

다른 이름들:
  • 테즈스파이어®

AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

다른 이름들:
  • SYMBICORT® pMDI

AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

다른 이름들:
  • AIRSUPRA®

NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

다른 이름들:
  • 아리돌®

AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation

다른 이름들:
  • 사부마린, 알부테롤, 벤톨린 HFA, 프로에어 HFA, 프로벤틸 HFA
실험적: Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS

No Asthma Control or Low Biomarkers - No Step-down of ICS

IMP. Subcutaneous injection. Unit dose strengths 210 mg.

다른 이름들:
  • 테즈스파이어®

AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

다른 이름들:
  • SYMBICORT® pMDI

AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

다른 이름들:
  • AIRSUPRA®

NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

다른 이름들:
  • 아리돌®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.
기간: Week 56

Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase to either:

Outside of the US:

  • Medium-dose maintenance and reliever therapy, or
  • Low-dose maintenance and reliever therapy, or
  • SYMBICORT® anti-inflammatory reliever only

In the US:

  • Medium-dose SYMBICORT® and AIRSUPRA®,or
  • Low-dose SYMBICORT® and AIRSUPRA®, or
  • AIRSUPRA® only
Week 56

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients in asthma control
기간: Week 24

Proportion of patients in asthma control at Week24.

Week 24
Proportion of patients with characteristics of clinical remission
기간: Week 24

Proportion of patients with characteristics of clinical remission at Week 24

Week 24
Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24
기간: Week 56

Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 56
Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24
기간: Week 72

Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 72
Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24
기간: Week 56 and Week 72

Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 56 and Week 72
Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
기간: Week 56

Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

Week 56
Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
기간: Week 72

Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

Week 72
Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24
기간: Week 56

Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 56
Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24
기간: Week 72

Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 72
Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24
기간: Week 56 and Week 72

Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

Week 56 and Week 72
Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
기간: Week 56

Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

Week 56
Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
기간: Week 72

Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

Week 72
Proportion of patients in complete remission at Week 56
기간: Week 56

Proportion of patients in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Week 56
Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56
기간: Week 72

Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Week 72
Change from Week 24 at Week 56 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)
기간: From Week 24 at Week 56

Change from Week 24 at Week 56 in:

  • Mean monthly maintenance ICS dose
  • Mean monthly rescue ICS dose
  • Mean monthly total ICS dose (maintenance and rescue doses)
From Week 24 at Week 56
Change from Week 24 at Week 72 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)
기간: From Week 24 at Week 72

Change from Week 24 at Week 72 in:

  • Mean monthly maintenance ICS dose
  • Mean monthly rescue ICS dose
  • Mean monthly total ICS dose (maintenance and rescue doses)
From Week 24 at Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56
기간: Between Week 24 and Week 56

Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 24 and Week 56
Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72
기간: Between Week 56 and Week 72

Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 56 and Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72
기간: Between Week 24 and Week 72

Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 24 and Week 72
AAER between Week 0 and Week 24 among all tezepelumab-treated patients
기간: Between Week 0 and Week 24

Annualised Asthma Exacerbation Rate between Week 0 and Week 24 among all tezepelumab-treated patients.

Between Week 0 and Week 24
AAER between Week 24 and Week 56
기간: Between Week 24 and Week 56

Annualised Asthma Exacerbation Rate between Week 24 and Week 56 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 24 and Week 56
AAER between Week 56 and Week 72
기간: Between Week 56 and Week 72

Annualised Asthma Exacerbation Rate between Week 56 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 56 and Week 72
AAER between Week 24 and Week 72
기간: Between Week 24 and Week 72

Annualised Asthma Exacerbation Rate between Week 24 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Between Week 24 and Week 72
ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients
기간: From baseline at Week 24

ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients

From baseline at Week 24
ACQ-5 score and changes from Week 24 at Week 56
기간: From Week 24 at Week 56

ACQ-5 score and changes from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 56
ACQ-5 score and changes from Week 24 at Week 72
기간: From Week 24 at Week 72

ACQ-5 score and changes from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 72
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.
기간: From baseline at Week 24

Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.

From baseline at Week 24
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56
기간: From Week 24 at Week 56

Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 56
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72
기간: From Week 24 at Week 72

Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 72
SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.
기간: From baseline at Week 24

SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.

From baseline at Week 24
SGRQ total score and changes from Week 24 at Week 56
기간: From Week 24 at Week 56

SGRQ total score and changes from Week 24 at Week 56, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 56
SGRQ total score and changes from Week 24 at Week 72
기간: From Week 24 at Week 72

SGRQ total score and changes from Week 24 at Week 72, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 72
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients.
기간: From baseline at Week 24

Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients

From baseline at Week 24
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56
기간: From Week 24 at Week 56

Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 56
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72
기간: From Week 24 at Week 72

Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

From Week 24 at Week 72
Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.
기간: Baseline at Week 24

Asthma exacerbations, patient-reported outcomes, and lung function. Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.

Baseline at Week 24
Pre-BD FEV1 total score and changes from Week 24 at Week 56
기간: From Week 24 at Week 56

Pre-BD FEV1 total score and changes from Week 24 at Week 56, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.

From Week 24 at Week 56
Pre-BD FEV1 total score and changes from Week 24 at Week 72
기간: From Week 24 at Week 72

Pre-BD FEV1 total score and changes from Week 24 at Week 72, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.

From Week 24 at Week 72
Proportion of pre-BD FEV1 responders from baseline at Week 24
기간: Week 24

Proportion of pre-BD FEV1 responders from baseline (defined as patients who achieve either a≥ 5% or ≥ 100 mL improvement from baseline) at Week 24, for all tezepelumab-treated patients

Week 24
Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24
기간: Week 56

Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Week 56
Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24
기간: Week 72

. Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

Week 72

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 9월 30일

기본 완료 (추정된)

2027년 6월 25일

연구 완료 (추정된)

2027년 6월 25일

연구 등록 날짜

최초 제출

2024년 6월 10일

QC 기준을 충족하는 최초 제출

2024년 6월 19일

처음 게시됨 (실제)

2024년 6월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 12일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • D5180C00047

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .